Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Invest Dermatol. 2018 Feb 13;138(7):1539–1545. doi: 10.1016/j.jid.2018.01.032

Figure 3. Molecular analysis of skin biopsies taken from patients during a clinical trial of tofacitinib citrate.

Figure 3.

(a) 24 weeks of treatment corresponds with significant shifts in molecular profile of scalp biopsies. (b). ALADIN signature scoring accurately predicts and reflects response to treatment using a disease signature.